Distribution of a vaginal gel (Invisible Condom®) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study

Contraception

Volumn 77, Issue 6, 2008, Pages 447-455

  Omar, Rabeea F ^a   Trottier, Sylvie ^a   Brousseau, Ghislain ^b   Lamarre, André ^b   Alexandre Gagnon, ^b   Bergeron, Michel G ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Distribution; Microbicide; MRI; Persistence, simulated sex; Vaginal gel

Indexed keywords

CLINDAMYCIN; CONTRACEPTIVE AGENT; INVISIBLE CONDOM;

ADULT; ARTICLE; CONDOM; CONTROLLED STUDY; CREAM; DRUG DISTRIBUTION; DRUG FORMULATION; EVALUATION; FEMALE; GEL; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SEXUAL INTERCOURSE; SIMULATION; UTERINE CERVIX MUCOSA; VAGINA CONTRACEPTION;

EID: 43249113043     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.01.015     Document Type: Article

References (24)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) AIDS epidemic update: December 2006 http:www.unaids.org/en/HIV_data/epi2006 . Accessed November 23, 2006
2. WHO Global prevalence and incidence of selected curable sexually transmitted infections. Overview and estimates. Reference no. WHO/HIV_AIDS/2001.02 2001 http://www.who.int/hiv/pub/sti/pub7/en/index.html , Page access verified on August 31, 2007
3. A. Glasier A.M. Gulmezoglu G.P. Schmid C.G. Moreno P.F.A. VanLook Sexual and reproductive health: a matter of life and death Lancet 368 2006 1595 1607
4. WHO The world health report 2002 — reducing risks, promoting healthy life 2002 http://www.who.int/whr/2002/en/ . Accessed October 2004
5. R.C. Bailey S. Moses C.B. Parker K. Agot I. Maclean Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial Lancet 369 9562 2007 643 656
6. R.H. Gray G. Kigozi D. Serwadda F. Makumbi S. Watya Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial Lancet 369 9562 2007 657 666
7. R. Johnston Microbicides 2002: an update AIDS Patient Care STD 16 2002 419 430
8. J. Piret N. Gagne S. Perron Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and herpes simplex virus type 2 Sex Transm Dis 28 8 2001 484 491
9. S. Roy P. Gourde J. Piret Thermoreversible gel formulations containing sodium lauryl sulfate or n -lauroylsarcosine as potential topical microbicides against sexually transmitted diseases Antimicrob Agents Chemother 45 6 2001 1671 1681
10. N. Gagne H. Cormier R.F. Omar Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9 Sex Transm Dis 26 3 1999 177 183
11. J. Bestman-Smith J. Piret A. Desormeaux M.J. Tremblay R.F. Omar Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment Antimicrob Agents Chemother 45 8 2001 2229 2237
12. J. Piret S. Roy M. Gagnon Comparative study of mechanisms of herpes simplex virus inactivation by sodium lauryl sulfate and n -lauroylsarcosine Antimicrob Agents Chemother 46 9 2002 2933 2942
13. M.K. Howett E.B. Neely N.D. Christensen A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses Antimicrob Agents Chemother 43 2 1999 314 321
14. C. Haineault P. Gourde S. Perron Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device Biol Reprod 69 2003 687 694
15. J. Piret G. Laforest M. Bussières M.G. Bergeron Subchronic (26- and 52-week) toxicity and irritation studies of a novel microbicidal gel formulation containing sodium lauryl sulfate in animal models J Appl Toxicol 2007 [Electronic publication ahead of print; DOI: 10.1002/jat.1262]
16. Bergeron MG Omar RF Désormeaux A Gagnon MT Vezina F Trottier S Phase I clinical trial to evaluate the safety and acceptability of the Invisible Condom when applied intravaginally to healthy female subjects Microbicide 2002” Meeting, Antwerp, Belgium 2002
17. S. Trottier R.F. Omar A. Désormeaux J. Drouin M.T. Gagnon Safety, tolerance and acceptability of the Invisible CondomÒ and its vaginal applicator in healthy women and their male sexual partners Contraception 76 2 2007 117 125
18. R.P. Nugent M.A. Krohn S.L. Hillier Reliability of diagnosis bacterial vaginosis is improved by a standardized method of Gram stain interpretation J Clin Microbiol 29 1991 297 301
19. K.T. Barnhart E.S. Pretorius A. Stolpen D. Malamud Distribution of topical medication in the human vagina as imaged by magnetic resonance imaging Fertil Steril 76 1 2001 189 195
20. J.G. Vail J.A. Cohen K.L. Kelly Improving topical microbicides applicators for use in resource-poor settings Am J Public Health 94 7 2004 1089 1091
21. K.T. Barnhart E.S. Pretorius K. Timbers D. Shera M. Shabbout In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse Contraception 70 2004 498 505
22. E.S. Pretorius K. Timbers D. Malamud K.T. Barnhart Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during and after both simulated and real intercourse Contraception 66 2002 443 451
23. K.T. Barnhart E.S. Pretorius K. Timbers D. Shera M. Shabbout Distribution of a 3.5-mL (1.0%) C31G vaginal gel using magnetic resonance imaging Contraception 71 2005 357 361
24. J. Juhasz C. Pimienta V. Lenaerts Adhesion of poloxamer 407 formulations on dog ileal segments in vitro Eur J Pharm Biopharm 37 4 1991 262 265